Login to Your Account



GSK Opts Out of Two Cancer Programs with Cytokinetics

By Catherine Hollingsworth


Monday, December 29, 2008
Cytokinetics Inc. received some disappointing news just before the holidays, as longtime partner GlaxoSmithKline plc decided to take a pass on developing two early stage cancer compounds. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription